Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting.
HistoSonics has developed a system to destroy tumors completely non-invasively. Treatment is achieved using histotripsy, a novel form of energy that is safe, extremely precise, and able to be personalized for each patient. The initial indication is for treatment of liver tumors and the system is being studied in several other types of tumors.